Takeda's Rich Pipeline Optionality Is Worth A 'Buy'
Takeda Pharmaceutical Company Limited is facing a revenue dip for FY2025, primarily due to the impact of generic competition on Vyvanse. The company is implementing a transformation program alongside a cost-cutting initiative aimed at achieving over $1.3 billion in annual savings by FY2028. Future growth is expected to hinge on the successful launch of three key candidates in the near term.
- ▪Takeda's FY2025 revenue is projected at $28.4 billion, reflecting a 1.7% year-over-year decline.
- ▪The decline is attributed to the pressure from generic versions of Vyvanse.
- ▪Takeda plans to implement a transformation program that includes a cost-saving plan targeting $1.3 billion by FY2028.
- ▪The company's long-term growth strategy relies on the upcoming launches of oveporexton, rusfertide, and zasocitinib.
Seeking Alpha files mainly under finance. We currently carry 6,371 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4905965-takedas-rich-pipeline-optionality-is-worth-a-buy"},"author":{"@type":"Person","name":"Myriam…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
